急性缺血性脑卒中患者血清PRDX1、Sestrin2水平与病情及预后的关系

Correlation of serum Sestrin 2 and PRDX1 with prognosis of patients with acute ischemic stroke

摘要:

目的 探讨急性缺血性脑卒中患者血清过氧化还原蛋白1（PRDX1）、Sestrin2水平与病情及预后的关系。方法 选取2016年7月—2018年2月于邯郸市中心医院收治的急性缺血性脑卒中患者98例作为急性缺血性脑卒中组，依据卒中量表（NIHSS）评分分为轻度组、中度组和重度组，依据改良RANKIN量表（mRS）评分分为预后良好组和预后不佳组，另选取同期于该院体检的健康群众90例作为对照组，比较各组血清PRDX1、Sestrin2水平，并分析血清PRDX1、Sestrin2水平与NIHSS评分、mRS评分的相关性，采用多因素Logistic回归模型分析急性缺血性脑卒中患者预后的影响因素。结果 急性缺血性脑卒中组血清PRDX1、Sestrin2水平较对照组高（P <0.05）；轻度组血清PRDX1、Sestrin2水平低于中度组，中度组低于重度组（P <0.05）；预后良好组血清PRDX1、Sestrin2水平低于预后不佳组（P <0.05）。Pearson相关分析显示，急性缺血性脑卒中组血清PRDX1、Sestrin2水平与NIHSS评分呈正相关（r =0.647和0.842，均P <0.05），与mRS评分呈正相关（r =0.717和0.805，均P <0.05）。多因素Logistic回归分析显示，血清PRDX1［R=3.765（95% CI：1.369，7.206），P <0.05］、Sestrin2［R=2.748（95% CI：0.853，6.071），P <0.05］、合并高血压［R=2.063（95% CI：0.824，4.976），P <0.05］是急性缺血性脑卒中预后的危险因素。结论 急性缺血性脑卒中患者血清PRDX1、Sestrin2水平异常升高，且与病情和预后密切相关，检测血清PRDX1、Sestrin2及是否合并高血压有助于急性缺血性脑卒中的病情判断及预后评估。

Abstract:

Objective To explore the relationship of serum recombinant peroxiredoxin 1 (PRDX1) and Sestrin2 with the condition and prognosis of patients with acute ischemic stroke (AIS).Methods A total of 98 patients with AIS who were admitted to our hospital from July 2016 to February 2018 were selected as AIS group. They were divided into mild group, moderate group, and severe group according to the score of stroke scale (NIHSS). According to the modified RANKIN scale (mRS), they were divided into good prognosis group and poor prognosis group. Another 90 healthy people in our hospital during the same period were selected as control group. The levels serum of PRDX1 and Sestrin2 in each group were compared, and the correlation between the serum of PRDX1, Sestrin2 and NIHSS score, mRS score were analyzed. Multivariate logistic regression models were used to analyze the influencing factors of prognosis of patients with AIS.Results The levels of serum PRDX1 and Sestrin2 in AIS group were higher than those in control group, the differences were statistically significant (P < 0.05). The levels of serum PRDX1 and Sestrin2 in mild group were lower than those in moderate group, and those in moderate group were lower than those in severe group, the differences were statistically significant (P < 0.05). The levels of serum PRDX1 and Sestrin2 in good prognosis group were lower than those in poor prognosis group, the differences were statistically significant (P < 0.05). Pearson correlation analysis results showed that the levels of serum PRDX1 and Sestrin2 were positively correlated with NIHSS and mRS scores in AIS group [r = 0.647, 0.842, 0.717 and 0.805, (all P < 0.05)]. Multivariate logistic regression analysis showed that levels of serum PRDX1 [R =3.765, (95% CI: 1.369, 7.206), Sestrin2 [R = 2.748, (95% CI: 0.853, 6.071)], and concomitant hypertension [R = 2.063, (95% CI: 0.824, 4.976) were risk factors for the prognosis of AIS (all P < 0.05).Conclusion The levels of serum PRDX1 and Sestrin2 in patients with AIS are abnormally elevated, which are closely related to the condition and prognosis of AIS. The determination of serum PRDX1 and Sestrin2 is helpful to the judgment of the condition and prognosis of AIS.